

What is claimed is

1. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in a patient infected with HCV genotype 1, wherein interferon and ribavirin are not to be administered to said patient, and said treatment lasts for 12 weeks, and wherein said at least two DAAs comprise:
Compound 1 having formula of




or a pharmaceutically acceptable salt thereof, and Compound 4 having formula of



or a pharmaceutically acceptable salt thereof, wherein Compound 1 or the salt thereof is to be co-administered with ritonavir.


2. The use of claim 1, wherein said patient is a treatment-naïve patient.

3. The use of claim 1, wherein said at least two DAAs further comprise compound 2 having formula of



or a pharmaceutically acceptable salt thereof.

4. The use of claim 2, wherein said at least two DAAs further comprise compound 2 having formula of



or a pharmaceutically acceptable salt thereof.

5. The use of claim 1, wherein said patient is infected with HCV genotype 1a.

6. The use of claim 2, wherein said patient is infected with HCV genotype 1a.

7. The use of claim 3, wherein said patient is infected with HCV genotype 1a.

8. The use of claim 4, wherein said patient is infected with HCV genotype 1a.

9. Use of at least two direct acting antiviral agents (DAAs)) in the manufacture of a medicament for treatment of HCV in a patient infected with HCV genotype 1, wherein interferon and ribavirin are not to be administered to said patient, wherein said at least two DAAs comprise PSI-7977 and TMC-435, and wherein said treatment lasts for 12 weeks.

10. The use of claim 9, wherein said patient is a treatment-naïve patient.

11. The use of claim 9, wherein said patient is infected with HCV genotype 1a.

12. The use of claim 10, wherein said patient is infected with HCV genotype 1a.

13. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in a patient infected with HCV genotype 1, wherein interferon and ribavirin are not to be administered to said patient, wherein said at least two DAAs comprise PSI-7977 and GS-5885, and wherein said treatment as for 12 weeks.


14. The use of claim 13, wherein said patient is a treatment-naïve patient.

15. The use of claim 13, wherein said patient is infected with HCV genotype 1a.


16. The use of claim 14, wherein said patient is infected with HCV genotype 1a.

17. The use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in an HCV treatment-naïve patient infected with HCV genotype 1, wherein interferon and ribavirin are not to be administered to said patient, and said treatment lasts for 8 weeks, wherein said at least two DAAs comprise

Compound 1




Compound 2



and

Compound 4



and wherein Compound 1 is to be co-administered with ritonavir.

18. The use of claim 17, wherein Compound 1, ritonavir and Compound 4 are co-formulated in a single composition to be administered once daily, and Compound 2 is to be administered twice daily.

19 The use of claim 17, wherein Compound 1 is to be administered 150 mg once daily together with 100 mg of ritonavir once daily and Compound 4 is to be administered 25mg once daily, Compound 2 is to be administered 400mg twice daily.

20. The use of claim 17, wherein said patient is infected with HCV genotype 1a.

21. The use of claim 18, wherein said patient is infected with HCV genotype 1a.

22. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in an HCV treatment-naïve patient infected with HCV genotype 1, wherein interferon and ribavirin are not to be administered to said patient, and said treatment lasts for 8 weeks, and wherein said at least two DAAs comprise PSI-7977 and GS-5885.

23. The use of claim 22, wherein said two DAAs are to be administered once daily.

24. The use of claim 22, wherein said two DAAs are to be co-formulated in a single composition to be administered once daily.

25. The use of claim 22, wherein PSI-7977 is to be administered 400 mg once daily and GS-5885 is to be administered 90 mg once daily.

26. The use of claim 22, wherein said patient is infected with HCV genotype 1a.

27. The use of claim 23, wherein said patient is infected with HCV genotype 1a.

28. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in an HCV treatment-naïve patient infected with HCV genotype 1, wherein interferon and ribavirin are not to be administered to said patient, and said treatment lasts for 8, 9, 10, 11 or 12 weeks, and wherein said at least two DAAs comprise Compound 1, Compound 2 and Compound 4, or said at least two DAAs comprise PSI-7977 and GS-5885.

29. The use of claim 28, wherein said at least two DAAs comprise Compound 1, Compound 2 and Compound 4, and Compound 1 is to be co-administered with ritonavir.

30. The use of claim 29, wherein Compound 1, ritonavir and Compound 4 are co-formulated in a single composition to be administered once daily, and Compound 2 is to be administered twice daily.

31. The use of claim 29, wherein Compound 1 is to be administered 150 mg once daily together with 100 mg ritonavir once daily, Compound 4 is to be administered 25mg once daily, and Compound 2 is to be administered 400mg twice daily.

32. The use of claim 29, wherein said patient is infected with HCV genotype 1a.

33. The use of claim 28, wherein said at least two DAAs comprise PSI-7977 and GS-5885.


34. The use of claim 33, wherein said at least two DAAs are to be administered once daily.

35. The use of claim 33, wherein said two DAAs are co-formulated in a single composition and are to be administered once daily.

36. The use of claim 33, wherein said patient is infected with HCV genotype 1a.

37. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in an HCV patient, wherein said treatment lasts for 8 weeks, wherein interferon and ribavirin are not to be administered to said patient and said at least two DAAs comprise PSI-7977 and an HCV NS5A inhibitor, and wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

38. The use of claim 37, wherein said HCV NS5A inhibitor is Compound 4




39. The use of claim 37, wherein said PSI-7977 is to be administered 400 mg once daily.


40. The use of claim 37, wherein said PSI-7977 and said HCV NS5A inhibitor are co-formulated in a single composition to be administered once daily.

41. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in a patient infected with HCV genotype 1, wherein said treatment lasts for 6 or 7 weeks, wherein interferon and ribavirin are not to be administered to said patient, and said at least two DAAs comprise PSI-7977, an HCV NS5A inhibitor and another DAA.

42. The use of claim 41, wherein said another DAA is Compound 1



and said HCV NS5A inhibitor is Compound 4



43. The use of claim 41, wherein said PSI-7977 is to be administered at a dose of 400 mg once daily.

44. The use of claim 41, wherein said another DAA is an HCV protease inhibitor.

45. The use of claim 41, wherein said another DAA is an HCV polymerase inhibitor.

46. The use of claim 41, wherein said patient is a treatment naïve patient.

47. The use of claim 41, wherein said patient is an interferon non-responder.

WHAT IS CLAIMED IS:

1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient, wherein said treatment does not include administration of either interferon or ribavirin to said patient, and said treatment lasts for 8, 9, 10, 11 or 12 weeks.

2. The method of claim 1, wherein said at least two DAAs comprise:
Compound 1 or a pharmaceutically acceptable salt thereof, and
Compound 4 or a pharmaceutically acceptable salt thereof,
wherein Compound 1 or the salt thereof is co-administered with ritonavir.

3. The method of claim 2, wherein said treatment lasts for 12 weeks.

4. The method of claim 2, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

5. The method of claim 3, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

6. The method of claim 1, wherein said at least two DAAs comprise:
Compound 1 or a pharmaceutically acceptable salt thereof,
Compound 2 or a pharmaceutically acceptable salt thereof, and
Compound 4 or a pharmaceutically acceptable salt thereof,
wherein Compound 1 or the salt thereof is co-administered with ritonavir.

7. The method of claim 6, wherein said treatment lasts for 12 weeks.

8. The method of claim 6, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

9. The method of claim 7, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

10. The method of claim 1, wherein said at least two DAAs comprise PSI-7977 and TMC-435.

11. The method of claim 10, wherein said treatment lasts for 12 weeks.

12. The method of claim 10, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

13. The method of claim 11, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

14. The method of claim 1, wherein said at least two DAAs comprise PSI-7977 and daclatasvir.

15. The method of claim 14, wherein said treatment lasts for 12 weeks.

16. The method of claim 14, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

17. The method of claim 15, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

18. The method of claim 1, wherein said at least two DAAs comprise PSI-7977 and GS-5885.

19. The method of claim 18, wherein said treatment lasts for 12 weeks.

20. The method of claim 18, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

21. The method of claim 19, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

22. The method of claim 1, wherein said at least two DAAs comprise BMS-790052 and BMS-650032, and said treatment lasts for 10, 11 or 12 weeks

23. The method of claim 22, wherein said treatment lasts for 12 weeks.

24. The method of claim 22, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

25. The method of claim 23, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

26. The method of claim 1, wherein said at least two DAAs comprise mericitabine and danoprevir, and said treatment lasts for 12 weeks.

27. The method of claim 26, wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

28. The method of claim 1, wherein said at least two DAAs comprise INX-189 and daclatasvir.

29. A method of treatment for HCV, comprising administering PSI-7977 to a treatment-naïve patient who is infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, and said treatment lasts for 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 weeks.

30. The method of claim 29, wherein said treatment lasts for 12 weeks.